(-0.57%) 5 078.50 points
(-0.31%) 38 559 points
(-0.94%) 17 499 points
(0.05%) $82.85
(-1.09%) $1.635
(0.02%) $2 338.80
(0.31%) $27.43
(0.15%) $917.20
(-0.20%) $0.933
(-0.28%) $10.95
(-0.43%) $0.799
(-0.18%) $92.16
@ $40.50
Issued: 9 Apr 2024 @ 09:36
Return: -3.41%
Previous signal: Apr 8 - 12:23
Previous signal:
Return: 0.25 %
Live Chart Being Loaded With Signals
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally...
Stats | |
---|---|
Today's Volume | 597 776 |
Average Volume | 1.04M |
Market Cap | 4.97B |
EPS | $0 ( 2024-02-20 ) |
Next earnings date | ( $0.690 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 18.63 |
ATR14 | $0.0220 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Labarre Michael J. | Buy | 10 000 | Common Stock |
2024-04-17 | Labarre Michael J. | Sell | 10 000 | Common Stock |
2024-04-16 | Labarre Michael J. | Sell | 10 000 | Common Stock |
2024-04-16 | Labarre Michael J. | Sell | 10 000 | Option to Purchase Common Stock |
2024-04-17 | Labarre Michael J. | Sell | 10 000 | Option to Purchase Common Stock |
INSIDER POWER |
---|
15.86 |
Last 100 transactions |
Buy: 612 606 | Sell: 449 990 |
Volume Correlation
Halozyme Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
LWAC | 0.957 |
SRAC | 0.91 |
NETE | 0.889 |
AMRB | 0.889 |
ACER | 0.853 |
HOUR | 0.849 |
KNSA | 0.839 |
MMAC | 0.831 |
EEIQ | 0.829 |
WBA | 0.829 |
10 Most Negative Correlations | |
---|---|
TLGT | -0.945 |
SVAC | -0.942 |
GOODM | -0.919 |
SIBN | -0.88 |
RPHM | -0.88 |
PAIC | -0.872 |
SNPO | -0.86 |
MTSL | -0.85 |
PYXS | -0.845 |
XOG | -0.843 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Halozyme Therapeutics Inc Correlation - Currency/Commodity
Halozyme Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $829.25M |
Gross Profit: | $636.89M (76.80 %) |
EPS: | $2.13 |
Q4 | 2023 |
Revenue: | $230.04M |
Gross Profit: | $177.74M (77.27 %) |
EPS: | $0.660 |
Q3 | 2023 |
Revenue: | $216.03M |
Gross Profit: | $161.21M (74.62 %) |
EPS: | $0.620 |
Q2 | 2023 |
Revenue: | $221.04M |
Gross Profit: | $170.97M (77.35 %) |
EPS: | $0.570 |
Financial Reports:
No articles found.
Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators